---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-043362"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:29:42.941922+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma Q2 net loss $11.5M; cash only $26K; needs capital beyond May 2025

## Summary
- Net loss of $11.5M ($1.27 per share) for Q2 fiscal 2025 vs $8.5M a year ago.
- Cash and cash equivalents only $26,410 as of March 31, 2025.
- Company will need additional capital to support operations beyond May 2025.
- R&D expenses $3.8M; G&A expenses $4.8M, both up vs prior year.
- Plans to secure financing for LYMPHIR launch; retained Jefferies for strategic alternatives.

## SEC filing metadata
- accession: 0001213900-25-043362
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390025043362/0001213900-25-043362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390025043362/ea0241974-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-043362
- JSON: https://secwatch.observer/filing/0001213900-25-043362.json
- Plain text: https://secwatch.observer/filing/0001213900-25-043362.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.